Baird Medical Advances Clinical Education with Expert-Led Workshops in Indonesia
Rhea-AI Summary
Baird Medical (NASDAQ: BDMD) executed two expert-led clinical training workshops in Indonesia on March 16, 2026. The sessions at EKA Medika Hospital and RSCM Rumah Sakit Nasional Dr. Cipto Mangunkusumo Hospital delivered hands-on instruction in minimally invasive Microwave Ablation (MWA) platforms.
Attending physicians practiced MWA techniques for a variety of soft tissue conditions to support regional adoption and smoother clinical integration of Baird Medical's technologies across Southeast Asia.
Positive
- None.
Negative
- None.
News Market Reaction – BDMD
In the Mar 16 session, BDMD declined 4.17%, reflecting a moderate negative market reaction. Argus tracked a trough of -20.0% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Global clearance news | Positive | -14.3% | Regulatory clearance for MWA systems in Argentina expanding certifications. |
| Mar 09 | U.S. conference update | Positive | -7.4% | Showcase at NASIT 2026 to advance U.S. interventional thyroidology expansion. |
| Mar 04 | AI software milestone | Positive | +38.1% | Completion of AI-driven surgical software and start of global registrations. |
| Mar 02 | U.S. expansion event | Positive | -5.7% | Participation at NASOIE 2026 to support U.S. commercial expansion. |
| Feb 25 | U.S. clinical adoption | Positive | +29.0% | Expanded U.S. clinical use of MWA for benign thyroid conditions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-expansion press releases often saw negative or muted next-day moves, while technology-focused or major clinical adoption updates triggered stronger positive reactions.
Over the past few weeks, Baird Medical has repeatedly highlighted international and U.S. expansion of its minimally invasive microwave ablation technology. On Feb 25, U.S. clinical adoption news coincided with a 28.96% gain, while subsequent U.S. conference updates on Mar 2 and Mar 9 saw declines of 5.7% and 7.42%. A major AI-driven surgical software update on Mar 4 led to a 38.15% rise. The Mar 12 Argentina regulatory clearance then saw a 14.34% drop. Today’s Indonesia training workshops fit the ongoing global expansion narrative.
Key Terms
microwave ablation (MWA) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Hosted at EKA Medika Hospital and RSCM Rumah Sakit Nasional Dr. Cipto Mangunkusumo Hospital, the specialized sessions gave local physicians hands-on experience with Baird Medical's platforms. Through direct clinical training, attending specialists refined their techniques for treating a variety of soft tissue conditions. This close collaboration helps hospitals smoothly integrate these highly effective treatments into their clinical practice.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the
The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-advances-clinical-education-with-expert-led-workshops-in-indonesia-302714114.html
SOURCE BDMD